Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis

The Lancet Oncology 2026

View at publisher
Authors: Judith S E Quik, Marieke A. Vollebergh, Valesca P. Retèl, Karen van der Sluis, Willem J. Koemans, Rosa T. van der Kaaij, Madelon M. Voets, Misha D P Luyer, Irene E G van Hellemond, Bas P L Wijnhoven, Bianca Mostert, Richard van Hillegersberg
+12 more Nadia Haj Mohammad, Boudewijn van Etten, Derk Jan A. de Groot, Olli Helminen, Jakob Hedberg, Peter Cashin, Julie Lykke Harbjerg, Alexander A F A Veenhof, Koen J. Hartemink, Liudmila L. Kodach, Vincent van der Noort, Johanna W. van Sandick
DOI: 10.1016/s1470-2045(26)00144-0
Cited by: 3
References: 28

Fields of Study & Subjects

Intraperitoneal and Appendiceal Malignancies Gastric Cancer Management and Outcomes Intestinal and Peritoneal Adhesions

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
8
Pages
1031–1042
Publication date
8 July 2026
Language
EN